Retatrutide is a next-generation triple hormone receptor agonist currently in late-stage clinical trials for weight management. Developed by Eli Lilly, it is the first investigational drug to simultaneously target GIP, GLP-1, and glucagon receptors, a triple-agonist approach that sets it apart from every obesity treatment currently on the market.
Get on the Waiting List
Enter your email below and we will send you one notification when retatrutide becomes available. No spam, no extras.
What Is Retatrutide?
Most people familiar with GLP-1 medications know semaglutide (the active ingredient in Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound). Those drugs target one or two hormone receptors involved in appetite regulation and metabolism. Retatrutide goes a step further by engaging a third receptor — the glucagon receptor — which plays a direct role in energy expenditure and fat breakdown.
This triple-agonist mechanism is why researchers and clinicians have been paying close attention to the drug’s clinical trial results. In a Phase 2 trial published in the New England Journal of Medicine, participants receiving the highest dose of retatrutide lost an average of 24.2% of their body weight over 48 weeks. That figure exceeded the weight loss observed in comparable trials of tirzepatide and semaglutide at similar time points.
Eli Lilly is now running multiple Phase 3 trials to evaluate retatrutide’s safety and efficacy across larger patient populations, including studies focused on obesity, type 2 diabetes, and obstructive sleep apnea related to excess weight.
Quick Facts
- Developer: Eli Lilly
- Type: GIP/GLP-1/Glucagon agonist
- Delivery: Once-weekly injection
- Phase: Phase 3 clinical trials
- Studied for: Obesity, Type 2 diabetes, sleep apnea
Core Benefits Under Investigation
Greater Weight Reduction
Phase 2 data showed up to 24% body weight loss over 48 weeks, outpacing results seen with existing GLP-1 medications in similar trial designs.
Triple Receptor Activation
By targeting GIP, GLP-1, and glucagon receptors simultaneously, retatrutide addresses appetite, blood sugar regulation, and energy expenditure in a single treatment.
Metabolic Health Improvements
Trial participants saw improvements in blood sugar levels, blood pressure, and cholesterol markers beyond what weight loss alone would typically produce.
Once-Weekly Dosing
Like other GLP-1 medications, retatrutide is designed as a once-weekly subcutaneous injection, keeping the treatment regimen simple and manageable.
Why Sign Up Now?
Retatrutide has not yet been approved by the FDA, and no specific approval date has been announced. However, given the strength of its Phase 2 results and the pace of Eli Lilly’s ongoing Phase 3 program, many analysts expect a regulatory submission within the next one to two years. If the Phase 3 data is consistent with earlier results, retatrutide could become one of the most effective prescription weight management options available.
By joining the waiting list, you will receive a single email notification when retatrutide receives FDA approval or becomes available through clinical access programs. We will not share your email address with third parties or send unrelated communications.